Cargando…
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
BACKGROUND: Renal cell carcinoma (RCC) responds to agents that inhibit vascular endothelial growth factor (VEGF) pathway. Sorafenib, a multikinase inhibitor of VEGF receptor, is effective at producing tumor responses and delaying median progression free survival in patients with cytokine refractory...
Autores principales: | Wang, Xiaoen, Zhang, Liang, Goldberg, S Nahum, Bhasin, Manoj, Brown, Victoria, Alsop, David C, Signoretti, Sabina, Mier, James W, Atkins, Michael B, Bhatt, Rupal S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258225/ https://www.ncbi.nlm.nih.gov/pubmed/22188900 http://dx.doi.org/10.1186/1479-5876-9-220 |
Ejemplares similares
-
Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
por: Zhang, Liang, et al.
Publicado: (2011) -
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2016) -
The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma()
por: Wang, Xiaoen, et al.
Publicado: (2014) -
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
por: Wang, X, et al.
Publicado: (2013) -
Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)